KR101201549B1 - Pharmaceutical and health food composition for preventing or treating rheumatoid arthritis comprising extracts of Eucommia ulmoides as effective component - Google Patents
Pharmaceutical and health food composition for preventing or treating rheumatoid arthritis comprising extracts of Eucommia ulmoides as effective component Download PDFInfo
- Publication number
- KR101201549B1 KR101201549B1 KR1020090122833A KR20090122833A KR101201549B1 KR 101201549 B1 KR101201549 B1 KR 101201549B1 KR 1020090122833 A KR1020090122833 A KR 1020090122833A KR 20090122833 A KR20090122833 A KR 20090122833A KR 101201549 B1 KR101201549 B1 KR 101201549B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- rheumatoid arthritis
- preventing
- present
- bark
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 63
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 26
- 235000013402 health food Nutrition 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 11
- 241000208689 Eucommia ulmoides Species 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 4
- 241000208125 Nicotiana Species 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 210000002997 osteoclast Anatomy 0.000 abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract description 7
- 230000000169 anti-osteoclastic effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 235000013527 bean curd Nutrition 0.000 abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- -1 olive oil Chemical compound 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 2
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 항염증 활성과 파골세포 억제 효과를 갖는 두충 추출물, 상기 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물 및 상기 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 개선용 건강기능식품에 관한 것이다.The present invention is a worm extract having anti-inflammatory activity and osteoclast inhibitory effect, a pharmaceutical composition for preventing or treating rheumatoid arthritis containing the extract as an active ingredient and a health functional food for preventing or improving rheumatoid arthritis containing the extract as an active ingredient. It is about.
본 발명의 두충 추출물은 류마티스 관절염에 유용한 물질로서, 류마티스에 관련된 질병의 예방제 및 치료제로서 뛰어난 효능이 있다.Tofu extract of the present invention is a useful material for rheumatoid arthritis, has excellent efficacy as a preventive and therapeutic agent for diseases related to rheumatoid arthritis.
두충, 열수 추출물, 류마티스 관절염, 약학 조성물, 건강기능식품 Tofu, hot water extract, rheumatoid arthritis, pharmaceutical composition, dietary supplement
Description
본 발명은 두충 추출물을 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 약학 조성물 및 건강식품 조성물에 관한 것으로, 보다 상세하게는 항염증 활성과 파골세포 억제 효과를 갖는 두충 추출물, 상기 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물 및 상기 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 개선용 건강기능식품에 관한 것이다.The present invention relates to a pharmaceutical composition and a health food composition for preventing or treating rheumatoid arthritis, which contains the worm extract as an active ingredient. More specifically, the worm extract having an anti-inflammatory activity and inhibitory effect on osteoclasts, the extract as an active ingredient It relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and to a health functional food for preventing or improving rheumatoid arthritis containing the extract as an active ingredient.
염증이란 세균 유래의 농양으로서 조직에 침입하여 증식된 화농균류를 백혈구가 왕성히 탐식하여, 그 결과 생기는 백혈구의 사태, 균에 의해 장해를 받은 조직, 세포 파괴물 등이 조직 내 융해하여 농이 축적된 곳의 병리적 상태를 말하며, 소염작용이라 함은 침입균의 증식을 항균제 등에 의하여 억제하든가, 혹은 농양 중에 측정된 이물을 탐식하는 마크로파지(macrophage)를 활성화하여 그것들을 소화, 배설하는 기능을 높여서 농양의 치료과정이 촉진되는 것을 말한다. Inflammation is a bacterium-derived abscess that infiltrates tissues with purulent fungi, and white blood cells actively devour the resulting leukocytes, tissues that have been injured by bacteria, and cell debris. It refers to the pathological condition of the place, and the anti-inflammatory effect is to suppress the growth of invading bacteria by antibacterial agents, or to activate the macrophage that detects foreign substances measured during the abscess, and to increase the ability to digest and excrete them by abscesses. It means that the treatment process is accelerated.
일반적으로 염증반응은 생체의 세포나 조직에 어떠한 기질적 변화를 가져오는 침습이 가해질 때 그 손상부위를 수복재생하려고 하는 생체의 방어 반응과정이다. 따라서, 이러한 일련의 반응에는 국소의 혈관, 체액의 각종 조직세포, 면역관여 세포 등이 포함된다고 한다. In general, an inflammatory reaction is a defense process of a living body that attempts to repair and repair the damaged area when an invasion that causes some organic change in a living cell or tissue is applied. Therefore, such a series of reactions include local blood vessels, various tissue cells of body fluids, immune-involved cells, and the like.
현재까지 항염증 물질들은 급성염증에서만 치료효과를 가지고 있지만, 류마티스 관절염과 같은 만성염증에서는 1차적인 염증 현상만을 완화할 뿐이며, 면역학적 치료효과는 기대할 수 없다고 보고되어 있다. 한편 근래에는 하이드록시 에이코사테트라에노익산 (hydroxy-eicosatetraenoic acid: HETE), 류코트리엔 B4, 류코트리엔 C4 등에 관하여 연구가 진행되고 있으며 이는 만성 염증에서 약간의 효과를 나타내고 있다(Huskisson. E. D. et al. Inflammation, Mechanism and Treatment, MTP, Lancaster, England, p. 55 (1980)).To date, anti-inflammatory substances have therapeutic effects only in acute inflammation, but in chronic inflammation such as rheumatoid arthritis, it is reported that only the primary inflammatory phenomenon is alleviated, and immunological therapeutic effects cannot be expected. Recently, studies on hydroxy-eicosatetraenoic acid (HETE), leukotriene B4, and leukotriene C4 have been conducted, which has some effects on chronic inflammation (Huskisson. ED et al. Inflammation). , Mechanism and Treatment, MTP, Lancaster, England, p. 55 (1980)).
인체의 뼈는 매일 조금씩 분해되고, 분해된 양만큼 새로운 뼈로 채워짐으로써 항상성을 유지하는 매우 역동적인 기관이다. 뼈를 분해하는 파골세포 (Osteoclast)와 뼈를 재생하는 조골세포(Osteoblast)는 항상성을 유지하는데, RANKL(Receptor Activator of NF-κB Ligand)는 염증 전구 단백질이며 파골세포 표면 수용체 단백질이다. 뼈를 흡수하는 파골세포의 활성이 증가하게 되면, 뼈의 분해가 촉진, 뼈가 얇아지고 쉽게 부러지는 골다공증과 같은 질병이 일어나게 되며, 조골세포의 활성이 증가하게 되면, 골밀도의 증가로 뼈의 기형이나 골석화증이 일어나게 된다. 따라서 파골세포 분화와 활성의 증가는 치주염, 골다공증, 관절염 등과 같은 뼈의 파괴를 가져오게 된다. The bones of the human body are a very dynamic organ that maintains homeostasis by breaking down little by little each day and filling it with new bone in the amount broken down. Osteoblasts that break down bone (Osteoclast) and osteoblasts that regenerate bone maintain homeostasis, RANKL (Receptor Activator of NF-κB Ligand) is an inflammatory precursor protein and osteoclast surface receptor protein. Increased activity of osteoclasts, which absorb bones, promotes bone breakdown, thinner and more easily broken osteoporosis, and when osteoblast activity increases, bone density increases with bone density. Or osteoporosis will occur. Thus, osteoclast differentiation and increased activity result in bone destruction such as periodontitis, osteoporosis and arthritis.
류마티스 관절염을 위한 약물요법으로 다양한 경구용 치료제가 사용되고 있으나 약물에 의한 부작용이 보고되고 있고, 천연물로부터의 류마티스 관절염 치료를 위한 물질의 종류는 한정되어 있어, 이에 대해 천연물로부터 류마티스 관절염 치료를 위한 안전한 물질 개발에 대한 연구가 요구되고 있는 실정이다.Various oral therapeutics have been used as a pharmacotherapy for rheumatoid arthritis, but side effects due to drugs have been reported, and the types of substances for the treatment of rheumatoid arthritis from natural products are limited, which is a safe substance for treating rheumatoid arthritis from natural products. Research on development is required.
두충(Eucommia ulmoides)은 두충나무과(Eucommiaceae)에 속하는 낙엽교목으로, 중국사천성 부근이 원산지이며 은행나무처럼 암수 딴 그루이고 1과 1속 1종에 속하는 희귀한 수목이다. 두충의 약리 작용을 보면, 혈관 평활근에 직접적인 확장작용을 일으켜 혈압을 내리며, 항노화작용이 있고, 혈중 콜레스테롤치를 강화시키는데, 두충의 잎은 관상동맥 혈류량을 증가시킨다. 또한, 동물의 부신피질 호르몬을 증강시키며 항염증작용을 보이고, 진정 진통작용과 신체 면역 기능을 조절하여 세포면역의 억제와 증강작용을 보인다. 또한, 출혈시간을 단축시키고, 이뇨작용도 나타내며, 항알레르기 작용과 자궁수축 작용이 있다. Eucommia ulmoides ) is a deciduous tree belonging to the genus Eucommiaceae. It is native to Sichuan , China , and is a rare tree belonging to the genus 1 and 1 genus. The pharmacological action of the larvae leads to direct dilation of vascular smooth muscle, lowering blood pressure, anti-aging and strengthening blood cholesterol levels. The larva leaves increase coronary blood flow. In addition, it enhances the adrenal cortex hormone of the animal and shows anti-inflammatory action, and it shows the suppression and enhancement of cellular immunity by regulating calming analgesic and body immune function. In addition, the bleeding time is shortened, diuretic action is also shown, there are anti-allergic action and uterine contraction action.
한국특허공개 제2001-0018321호에는 류마티스 관절염 환자를 위한 건강식품 조성물이 개시되어 있으며, 한국특허공개 제2005-0078080호에는 관절염 치료용의 제약학적 조성물 및 그 제조방법이 개시되어 있다.Korean Patent Publication No. 2001-0018321 discloses a health food composition for rheumatoid arthritis patients, and Korean Patent Publication No. 2005-0078080 discloses a pharmaceutical composition for treating arthritis and a method of manufacturing the same.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 이와 같은 점들을 감안하여 항염증 활성과 파골세포 억제 효과를 갖는 두충 추출물의 관절염에 대한 예방 또는 치료 효능을 규명함으로써 본 발명을 완성하였다.The present invention was derived by the above requirements, the present invention has completed the present invention by identifying the efficacy of preventing or treating arthritis of the worms extract having anti-inflammatory activity and osteoclast inhibitory effect in view of these points. .
상기 과제를 해결하기 위해, 본 발명은 항염증 활성과 파골세포 억제 효과를 갖는 두충 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물을 제공한다.In order to solve the above problems, the present invention provides a pharmaceutical composition for the prevention or treatment of rheumatoid arthritis, containing as an active ingredient a worm extract having anti-inflammatory activity and osteoclast inhibitory effect.
또한, 본 발명은 항염증 활성과 파골세포 억제 효과를 갖는 두충 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing or improving rheumatoid arthritis, which contains as an active ingredient a tofu extract having anti-inflammatory activity and osteoclast suppression effect.
본 발명에 따르면, 본 발명의 두충 추출물은 항염증 활성과 파골세포 억제 효과를 가지므로, 류마티스 관절염 환자를 위한 예방제 및 치료제 개발과 관련한 기능성 식품 및 약품 산업에 있어서 매우 유용하게 이용될 수 있다.According to the present invention, the worm extract of the present invention has anti-inflammatory activity and osteoclast inhibitory effect, and thus can be very useful in the functional food and pharmaceutical industry related to the development of preventive and therapeutic agents for rheumatoid arthritis patients.
본 발명의 목적을 달성하기 위하여, 본 발명은 항염증 활성과 파골세포 억제 효과를 갖는 두충 추출물을 제공한다.In order to achieve the object of the present invention, the present invention provides a worm extract having anti-inflammatory activity and osteoclast inhibitory effect.
본 발명의 두충 추출물의 상기 파골세포 억제는 RANKL(Receptor Activator of NF-κB Ligand)의 발현을 억제함으로써 수행될 수 있다.The osteoclast inhibition of the larvae extract of the present invention can be carried out by inhibiting the expression of Receptor Activator of NF-κB Ligand (RANKL).
또한, 본 발명은 본 발명의 두충 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis, containing the extract of the present invention as an active ingredient.
본 발명의 두충 추출물은 바람직하게는 두충 수피를 추출한 것이며, 더욱 바람직하게는 두충 수피를 열수 추출한 것이며, 더 더욱 바람직하게는 두충 수피 550-650 g을 물 10,000-14,000 ml에 넣고 90-100℃에서 2-4시간 동안 열수 추출한 다음 진공 농축기로 40-50℃에서 고형분이 25-35%가 될 때까지 농축하고, 농축물을 동결건조하여 수득할 수 있으며, 가장 바람직하게는 두충 수피 600 g을 물 12,000 ml에 넣고 100℃에서 3시간 동안 열수 추출한 다음 진공 농축기로 45℃에서 고형분이 30%가 될 때까지 농축하고, 농축물을 동결건조하여 수득할 수 있다.The larvae extract of the present invention is preferably extracted from the larva bark, more preferably from the hydrothermal extract of the larva bark, more preferably 550-650 g of the larva bark in 10,000-14,000 ml of water at 90-100 ℃ Hot water extraction for 2-4 hours, then concentrated in a vacuum concentrator at 40-50 ℃ until the solid content is 25-35%, and the concentrate can be obtained by lyophilization, most preferably 600 g of Peel bark It can be obtained by pouring into 12,000 ml, hot water extraction at 100 ° C. for 3 hours, and then concentrating at 45 ° C. until a solid content of 30% is obtained in a vacuum concentrator, and freezing-drying the concentrate.
본 발명은 또한, 두충 추출물을 유효성분으로 함유하는 류마티스 관절염 예방 또는 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing or improving rheumatoid arthritis, which contains the worm extract as an active ingredient.
본 발명의 건강기능식품에서, 두충 추출물은 바람직하게는 두충 수피를 추출한 것이며, 더욱 바람직하게는 두충 수피를 열수 추출한 것이며, 더 더욱 바람직하게는 두충 수피 550-650 g을 물 10,000-14,000 ml에 넣고 90-100℃에서 2-4시간 동안 열수 추출한 다음 진공 농축기로 40-50℃에서 고형분이 25-35%가 될 때까지 농축하고, 농축물을 동결건조하여 수득할 수 있으며, 가장 바람직하게는 두충 수피 600 g을 물 12,000 ml에 넣고 100℃에서 3시간 동안 열수 추출한 다음 진공 농축기로 45℃에서 고형분이 30%가 될 때까지 농축하고, 농축물을 동결건조하여 수득할 수 있다.In the dietary supplement of the present invention, the larvae extract is preferably extracted from the bark of the larvae, more preferably from the hydrothermal extract of the larvae bark, more preferably 550-650 g of the larva bark in 10,000-14,000 ml of water Hot water extraction at 90-100 ° C. for 2-4 hours and then concentrating at 40-50 ° C. with a vacuum concentrator until 25-35% solids, the concentrate can be obtained by lyophilization, most preferably tofu 600 g of bark may be added to 12,000 ml of water, hot water extracted at 100 ° C. for 3 hours, and then concentrated at 45 ° C. until the solid content reaches 30%, and the concentrate may be obtained by lyophilization.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 두충 추출물은 류마티스 관절염뿐만 아니라 다양한 염증질환과 뼈의 조직의 강성에도 유용하게 사용될 수 있다.The worm extract of the present invention can be usefully used not only for rheumatoid arthritis, but also for stiffness of various inflammatory diseases and bone tissues.
본 발명의 류마티스 관절염 예방 또는 치료용 약학 조성물은, 조성물 총 중량에 대하여 상기 추출물을 0.02 내지 80 중량%, 바람직하게는 0.02 내지 50 중량%로 포함할 수 있다.The pharmaceutical composition for preventing or treating rheumatoid arthritis of the present invention may include 0.02 to 80% by weight of the extract, preferably 0.02 to 50% by weight, based on the total weight of the composition.
본 발명의 추출물을 포함하는 약학조성물은 약학적 조성물의 제조에 통상적으로 사용하여 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.The pharmaceutical dosage forms of the extract of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in suitable aggregates.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화 합물 혹은 혼합물을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Pharmaceutical compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate Various compounds or mixtures, including cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate and sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어 떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. The administration may be carried out once a day or divided into several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다.The extract of the present invention can be administered to mammals such as rats, mice, livestock, humans and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
또한, 본 발명은 류마티스 관절염 예방 또는 개선 효과를 나타내는 상기 두충 추출물 및 식품학적으로 허용 가능한 식품보조첨가제를 포함하는 건강기능식품을 제공한다. 상기 두충 추출물은 바람직하게는 열수 추출물이다. 상기 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.In addition, the present invention provides a health functional food comprising the worm extract and food acceptable food supplements exhibiting an effect of preventing or improving rheumatoid arthritis. The larvae extract is preferably a hot water extract. Examples of the food to which the extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한, 당뇨병의 예방 또는 개선 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.It may also be added to foods or beverages for the purpose of preventing or improving diabetes. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. have.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물, 예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract, for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. . The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 추출물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있으며, 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components may be used independently or in combination, and the proportion of such additives is not so critical but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
실시예Example 1: 두충 추출물의 제조 1: Preparation of Tobacco Extract
두충 수피 600 g을 물 12,000 ml에 넣고 100℃에서 3시간 열수 추출한 다음 진공농축기로 45℃에서 고형분이 30%가 될 때까지 농축하고, 그 농축물을 동결건조하여 분말 150g을 수득하였다.600 g of Tobacco bark was added to 12,000 ml of water, extracted with hot water at 100 ° C. for 3 hours, and concentrated at 45 ° C. until the solid content reached 30%. The concentrate was lyophilized to obtain 150 g of powder.
실시예Example 2: 본 발명의 두충 추출물의 부종억제 효과 2: edema inhibitory effect of the worm extract of the present invention
윈터 등의 방법으로 카라지난 부종 억제 작용을 조사하였다. 150~200 g 수컷 흰쥐의 발바닥에 1%의 카라지난 0.1 ml를 피하주사하여 부종을 유발하고 검체는 카라지난 주사 30분 전에 경구투여하였다. 카라지난 주사 후 1시간 간격으로 4회에 걸쳐 부종의 용적을 용적측정기로 측정한 다음 주사 전의 용적을 기준으로 하여 그 증가율을 윈터 등의 방법(Winter, C. A. et al., Carrageenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs, Proc. Soc. Exp. Biol. Med., 111, 544 (1962))에 따라서 계산하여 부종 정도를 검정하였다. 대조약물 이부로펜 200 mg/kg을 경구투여하여 비교실험하였다. 실험결과 평균값과 표준오차를 사용하여 계산하였고 각 군간의 비교는 수튜던트 t-test를 사용하여 P값이 5% 미만일 때 통계학적으로 유의성이 있다고 판정하였다. The action of inhibiting carrageenan edema was investigated by the method of Winter et al. Edema was induced by subcutaneous injection of 0.1 ml of 1% carrageenan into the soles of 150-200 g male rats. Samples were orally administered 30 minutes before carrageenan injection. Measure the volume of edema four times at an interval of 1 hour after carrageenan injection, and then increase the rate based on the volume before injection (Winter, CA et al., Carrageenan-induced edema in hind). The degree of edema was calculated according to paw of the rat as an assay for anti-inflammatory drugs, Proc. Soc.Exp. Biol.Med., 111, 544 (1962)). Comparative experiment was performed by oral administration of the control drug ibulopene 200 mg / kg. The experimental results were calculated using the mean value and the standard error, and the comparison between each group was statistically significant when the P value was less than 5% using the Student's t-test.
그 결과, 부종 수치는 두충 추출물 투여군이 대조군에 비해서 낮은 수치를 보여, 두충 추출물이 부종억제 효능이 있음을 확인할 수 있었다 (도 1).As a result, the edema values showed a lower value than the control group to the worm extract extract, it was confirmed that the worm extract is effective in suppressing edema (Fig. 1).
실시예Example 3: 본 발명의 두충 추출물의 3: of the worm extract of the present invention 류마티스Rheumatism 관절염 억제 효과 Arthritis Inhibitory Effect
두충 추출물에 대한 류마티스 관절염 항염증작용을 알아보기 위해 DBA/1J 마우스 (6주령 25g, 수컷 (중앙실험동물))에 16주간 투여하였다. 관절염의 유발은 제2형 콜라겐(Sigma, USA)을 2 mg/ml의 농도로 0.1M 아세트산에 녹인 후 Freund's incomplete adjuvant (Sigma, USA)에 유화시켜 만들었다. 그 후 100㎕를 흰쥐의 우측 족척에 피하주사하였다. 일차 주사 후 7일 후 다시 꼬리기시부에 동량을 추가 접종하였고, 대조군에는 동량의 생리식염수를 접종하였다. 마지막 접종 일로부터 21일째에 육안으로 관절주위 발적, 부종 및 팽창을 형성하는 개체를 선별하여 실험하였다. 두충 추출물 투여시에는 두충 추출물 200 mg/kg을 0.9% 생리식염수에 녹여 membrane filter(pore size 0.2㎛, Whatman)로 여과한 후 1일 1회씩 16주 동안 경구 투여하였다.In order to investigate the anti-inflammatory effect of rheumatoid arthritis on the extract of the worms, DBA / 1J mice (6 weeks old 25g, males (Central experimental animals)) were administered for 16 weeks. Arthritis was induced by dissolving collagen type 2 (Sigma, USA) in 0.1 M acetic acid at a concentration of 2 mg / ml and then emulsifying it in Freund's incomplete adjuvant (Sigma, USA). 100 μl was then injected subcutaneously into the right foot of the rat. Seven days after the first injection, the same amount was further inoculated in the tail portion and the control group was inoculated with the same amount of saline. Individuals forming periarticular redness, edema and swelling were visually selected on day 21 after the last inoculation. When the worm extract was administered, 200 mg / kg of the worm extract was dissolved in 0.9% physiological saline, filtered through a membrane filter (pore size 0.2㎛, Whatman), and orally administered once a day for 16 weeks.
그 결과, 류마티스지수는 두충 추출물 투여군이 대조군에 비해서 낮은 수치를 보여, 이로 보아 두충 추출물이 류마티스 관절염 억제 효능이 있음을 확인할 수 있었다 (도 2).As a result, the rheumatoid index showed a lower value than the control group of the worm extract extract, it can be seen that the worm extract extracts are effective in inhibiting rheumatoid arthritis (Fig. 2).
실시예Example 4: 본 발명의 두충 추출물의 관절염무릎관절에서 4: arthritis knee joint of the present invention RANKLRANKL 억제 효과 Inhibitory effect
상기 실시예 3의 마우스를 16주 후에 에테르 마취하에서 혈액을 채취하고 무릎조직을 채취하여 탈회시킨 후 면역조직화학법을 실시하였다.After 16 weeks, the mice of Example 3 were subjected to immunohistochemistry after blood was collected under ether anesthesia, and knee tissue was collected and demineralized.
도 3은 두충 추출물의 RANKL의 저해 효과이다. 그림 A는 대조군으로 관절염무릎관절에서 RANKL의 발현을 보여주며, 그림 B는 두충 추출물을 투여한 군으로 관절염무릎관절에서 RANKL의 발현이 억제된 것을 알 수 있었다 (도 3).Figure 3 is an inhibitory effect of RANKL of the larvae extract. Figure A shows the expression of RANKL in the arthritis knee joint as a control, Figure B shows that RANKL expression was suppressed in the arthritis knee joint group to the group of administration of the extract of the worms (Fig. 3).
도 1은 두충 추출물의 부종 저해 효과이다.1 is the edema inhibitory effect of the larvae extract.
도 2는 두충 추출물의 류마티스지수 저해 효과이다.Figure 2 is a rheumatoid index inhibitory effect of the worms extract.
도 3은 두충 추출물의 RANKL의 저해 효과이다.Figure 3 is an inhibitory effect of RANKL of the larvae extract.
A: 대조군, B: 두충 추출물 투여군.A: control group, B: toxin extract administration group.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090122833A KR101201549B1 (en) | 2009-12-11 | 2009-12-11 | Pharmaceutical and health food composition for preventing or treating rheumatoid arthritis comprising extracts of Eucommia ulmoides as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090122833A KR101201549B1 (en) | 2009-12-11 | 2009-12-11 | Pharmaceutical and health food composition for preventing or treating rheumatoid arthritis comprising extracts of Eucommia ulmoides as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110066263A KR20110066263A (en) | 2011-06-17 |
| KR101201549B1 true KR101201549B1 (en) | 2012-11-15 |
Family
ID=44399125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090122833A KR101201549B1 (en) | 2009-12-11 | 2009-12-11 | Pharmaceutical and health food composition for preventing or treating rheumatoid arthritis comprising extracts of Eucommia ulmoides as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101201549B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160121032A (en) | 2015-04-09 | 2016-10-19 | 주식회사 중헌제약 | Pharmaceutical composition comprising 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol for treating and preventing inflammation and arthritis diseases |
| KR20240096003A (en) | 2022-12-19 | 2024-06-26 | 이진호 | Pharmaceutical health supplement composition for treating and preventing degenerative arthritis. |
| KR20240095994A (en) | 2022-12-19 | 2024-06-26 | 이진호 | Pharmaceutical health supplement composition for treating and preventing degenerative arthritis. |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101248378B1 (en) * | 2012-09-26 | 2013-04-02 | 대한약품공업 주식회사 | Pharmaceutical composition for arthritis treatment and prevention |
| CN104473998B (en) * | 2014-11-28 | 2018-07-20 | 河南恒瑞源实业有限公司 | A method of extraction Cortex Eucommiae fine powder simultaneously prepares activated carbon |
| CN104490984A (en) * | 2014-12-25 | 2015-04-08 | 井冈山大学 | Preparation method of eucommia bark superfine powder |
-
2009
- 2009-12-11 KR KR1020090122833A patent/KR101201549B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| Arch. Pharm. Res., Vol.26, No.11, pages 929-936 (2003). |
| Carbohydrate Research, Vol.344, pages 1319-1324. |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160121032A (en) | 2015-04-09 | 2016-10-19 | 주식회사 중헌제약 | Pharmaceutical composition comprising 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol for treating and preventing inflammation and arthritis diseases |
| US10265276B2 (en) | 2015-04-09 | 2019-04-23 | Chungbuk National University Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient |
| US10918609B2 (en) | 2015-04-09 | 2021-02-16 | Chungbuk National University Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient |
| KR20240096003A (en) | 2022-12-19 | 2024-06-26 | 이진호 | Pharmaceutical health supplement composition for treating and preventing degenerative arthritis. |
| KR20240095994A (en) | 2022-12-19 | 2024-06-26 | 이진호 | Pharmaceutical health supplement composition for treating and preventing degenerative arthritis. |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110066263A (en) | 2011-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101201549B1 (en) | Pharmaceutical and health food composition for preventing or treating rheumatoid arthritis comprising extracts of Eucommia ulmoides as effective component | |
| KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
| KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
| KR101341693B1 (en) | Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders | |
| KR102123832B1 (en) | Composition comprising herbal mixture extract for treating or preventing inflammatory disease | |
| KR100927101B1 (en) | Composition comprising Acer tegmentosum Maxim. extract or salidroside isolated from the same for preventing or treating gastritis and peptic ulcer | |
| KR20160006812A (en) | Compositions for preventing and curing diabetes comprising extract of Paeonia lactiflora | |
| KR101783119B1 (en) | Composition comprising the combined extracts of Schisandra chinensis, Eucommia ulmoides and Lycium barbarum for preventing or treating bone metabolism diseases | |
| KR102275492B1 (en) | Composition for Prevention or Treatment of Gastritis and Gastric ulcer Comprising Steamed Ginger Extract or 1-Dehydro-6-gingerdione Isolated therefrom as an Active Ingredient | |
| KR101016837B1 (en) | Composition comprising the extract of Lonicera japonica THUNB. preventing and treating arthritis | |
| KR102277057B1 (en) | Pharmaceutical composition comprising the extraction of cattail pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR102159686B1 (en) | Pharmaceutical composition comprising the extract of acorn pollen as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| KR101606773B1 (en) | Composition comprising oriental herbal extract for preventing or treating gastrointestinal disorder | |
| KR102114978B1 (en) | A Composition for Prevention and Treatment of Thyroid Disease including Coptidis Rhizoma Extract | |
| KR20120008366A (en) | A composition comprising the compound isolated from schisandra chinensis for preventing and treating colitis disease | |
| KR101332824B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising Euphorbia ebracteolata Extracts | |
| KR101787082B1 (en) | Composition comprising the extract of Platycodon grandiflorum enhanced effective saponin contents for treatment of rheumatoid arthritis | |
| KR100750873B1 (en) | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease | |
| KR20160089930A (en) | A composition for memory enhancement, comprising 5-HMF, paeoniflorin and betaine | |
| KR101899086B1 (en) | Composition for preventing, improving or treating liver damage | |
| KR20080094982A (en) | Composition comprising powder of tangerine peel or the extract thereof for treating and preventing gastrointestinal disease | |
| KR102463297B1 (en) | Novel use of extract of Artemisia annua | |
| KR102216221B1 (en) | Pharmaceutical composition comprising the extract of pine pollen as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20090089672A (en) | Composition comprising the extract of anemarrhena asphodeloides bunge. preventing and treating arthritis | |
| KR101219736B1 (en) | Composotion for facilitate secretion of testosterone comprising silk worm dry powder and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |